Elken Healthcare (01789) rose nearly 6%. As of press release, it was up 5.77% to HK$5.5, with a turnover of HK$9.2641 million.
The Zhitong Finance App learned that Elken Healthcare (01789) rose nearly 6%. As of press release, it had risen 5.77% to HK$5.5, with a turnover of HK$9.2641 million.
According to the news, recently, Elken Knee Surgery Robotic System (Knee Surgery Navigation and Positioning System) was approved for marketing by the National Drug Administration (NMPA). According to reports, the knee navigation and positioning system approved by the company this time consists of a robotic arm, an optical navigator, a trolley, control equipment and accessories. The surgical robot system guides knee osteotomy, soft tissue balance, and prosthesis implantation in real time during surgery, bringing more accurate and reliable results to the operation.
CITIC Construction Investment Securities pointed out that in the short term, after compliance in the medical industry is strengthened, the market gradually adapts, and the number of joint replacement surgeries is expected to resume high growth; at the same time, joint collection renewals are expected to be implemented in the near future. In the medium to long term, the penetration of joint replacement surgery in the country is still relatively low. Under the trend of population aging, the joint industry still has a lot of room for growth. The company actively lays out digital orthopedic platforms such as orthopedic navigation systems, surgical robots, and emerging fields of bone biomaterials, and is expected to maintain its leading position in the industry in the future with strong R&D capabilities, channel advantages, and brand advantages.